9:30–10:15 A.M.

Discussion with Speakers and Attendees

 
10:15–10:30 A.M.

BREAK

 
10:30 A.M.–12:15 P.M.

DRUG DISCOVERY AND DEVELOPMENT: CASE STUDIES OF GENOMICS-BASED DRUG DEVELOPMENT

Session Moderator: Michelle Penny, Eli Lilly and Company

 
10:30–10:50 A.M.

Development of Crizotinib for Treatment of Non-Small-Cell Lung Cancer

Steffan N. Ho
Director, Translational Oncology, Pfizer Inc.

 
10:50–11:10 A.M.

Use of Genetics to Inform Drug Development of a Novel Treatment for Schizophrenia

Laura Nisenbaum
Senior Research Advisor, Pharmacogenomics, Translational Medicine and Tailored Therapeutics, Eli Lilly and Company

 
11:10–11:30 A.M.

A Genetic Approach to the Treatment of Cystic Fibrosis

Peter Mueller
Executive Vice President, Global Research and Development; Chief Scientific Officer, Vertex Pharmaceuticals Incorporated

 
11:30 A.M.–12:15 P.M.

Discussion with Speakers and Attendees

 
12:15–1:00 P.M.

WORKING LUNCH



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement